| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1038/AJH.2010.169 |
| P698 | PubMed publication ID | 20706195 |
| P50 | author | Cristiana Catena | Q43271299 |
| GianLuca Colussi | Q50636769 | ||
| P2093 | author name string | Leonardo A Sechi | |
| Alessandro Di Fabio | |||
| P2860 | cites work | The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 |
| Intrarenal hemodynamics in primary aldosteronism before and after treatment. | Q30482375 | ||
| Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes | Q34068717 | ||
| Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction | Q34187441 | ||
| Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension | Q34610189 | ||
| Aldosterone-induced cardiac damage: focus on blood pressure independent effects | Q35041073 | ||
| CLINICAL CHARACTERISTICS OF PRIMARY ALDOSTERONISM FROM AN ANALYSIS OF 145 CASES. | Q35417596 | ||
| Is aldosterone bad for the heart? | Q35756497 | ||
| Aldosterone in the development and progression of renal injury | Q35807297 | ||
| Aldosterone as a cardiovascular risk factor. | Q36088724 | ||
| Primary aldosteronism: renaissance of a syndrome | Q36817162 | ||
| Primary aldosteronism: cardiovascular, renal and metabolic implications | Q37100027 | ||
| Primary aldosteronism: an update on screening, diagnosis and treatment. | Q37104618 | ||
| Aldosterone and the vascular system | Q37133549 | ||
| Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline | Q37190775 | ||
| Synergy of aldosterone and high salt induces vascular smooth muscle hypertrophy through up-regulation of NOX1. | Q39976757 | ||
| Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. | Q42467474 | ||
| Adipokines and cardiometabolic profile in primary hyperaldosteronism | Q43145610 | ||
| The dual role of the kidney in primary aldosteronism: key determinant in rescue from volume expansion and persistence of hypertension | Q43271237 | ||
| Renal damage in primary aldosteronism: results of the PAPY Study | Q43443868 | ||
| A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients | Q43565017 | ||
| Primary aldosteronism: an update on screening, diagnosis and treatment | Q43601908 | ||
| Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry | Q43641951 | ||
| Echocardiographic comparison of left ventricular structure and function in hypertensive patients with primary aldosteronism and essential hypertension | Q43980484 | ||
| Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism | Q44053688 | ||
| Aldosterone induces a vascular inflammatory phenotype in the rat heart | Q44182980 | ||
| Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone | Q44228479 | ||
| Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats | Q44390510 | ||
| Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study | Q44601096 | ||
| High rate of detection of primary aldosteronism, including surgically treatable forms, after ???non-selective??? screening of hypertensive patients | Q44642155 | ||
| Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. | Q44654274 | ||
| Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. | Q44786929 | ||
| Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension | Q44805596 | ||
| Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. | Q46033014 | ||
| Risk factors associated with a low glomerular filtration rate in primary aldosteronism | Q46179236 | ||
| Relative glomerular hyperfiltration in primary aldosteronism | Q46412561 | ||
| Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma | Q46433250 | ||
| Inappropriate left ventricular mass in patients with primary aldosteronism. | Q46470689 | ||
| Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study | Q46551755 | ||
| Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. | Q46571307 | ||
| Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis | Q46687570 | ||
| Prevalence and characteristics of the metabolic syndrome in primary aldosteronism | Q46807615 | ||
| Cardiovascular outcomes in patients with primary aldosteronism after treatment | Q46808203 | ||
| Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy | Q46878366 | ||
| Mineralocorticoid receptor activation and oxidative stress | Q46960438 | ||
| Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism | Q46983529 | ||
| Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats | Q48546780 | ||
| Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies | Q48854811 | ||
| Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. | Q50733892 | ||
| Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. | Q51034359 | ||
| Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. | Q51484111 | ||
| Diagnosis and treatment of primary hyperaldosteronism. | Q52363421 | ||
| Renal changes in primary aldosteronism | Q67542533 | ||
| Renal function curve in patients with secondary forms of hypertension | Q68162076 | ||
| Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles | Q68669670 | ||
| Prevalence of extracranial carotid artery lesions at duplex in primary aldosteronism | Q70547338 | ||
| Vasodilation to acetylcholine in primary and secondary forms of human hypertension | Q70744736 | ||
| Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan | Q71827885 | ||
| Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart | Q71844423 | ||
| Conn's syndrome and atrial fibrillation | Q74075941 | ||
| Cardiovascular complications in patients with primary aldosteronism | Q74451539 | ||
| Insulin sensitivity in patients with primary aldosteronism: a follow-up study | Q79844461 | ||
| Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension | Q80191642 | ||
| Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension | Q80466515 | ||
| Aldosterone and end-organ damage | Q80759232 | ||
| Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes | Q80797117 | ||
| Relationships of plasma renin levels with renal function in patients with primary aldosteronism | Q80797464 | ||
| Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism | Q81661632 | ||
| Long-term renal outcomes in patients with primary aldosteronism | Q83987126 | ||
| Mineralocorticoid receptors in myocardial infarction | Q84749469 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| P304 | page(s) | 1253-1260 | |
| P577 | publication date | 2010-08-12 | |
| P1433 | published in | Journal of Clinical Hypertension | Q15762840 |
| P1476 | title | Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment | |
| P478 | volume | 23 |
| Q89927231 | A case of monozygotic twins with primary aldosteronism: a case report |
| Q64055532 | Adrenalectomy Improves the Long-Term Risk of End-Stage Renal Disease and Mortality of Primary Aldosteronism |
| Q91915859 | Age-Dependent Progression of Renal Dysfunction After Adrenalectomy for Aldosterone-Producing Adenomas in Japan |
| Q38263511 | Aldosterone and the heart: still an unresolved issue? |
| Q38117211 | Aldosterone, organ damage and dietary salt. |
| Q46471215 | Analysis of various etiologies of hypertension in patients hospitalized in the endocrinology division |
| Q41595637 | Association of Post-Saline Load Plasma Aldosterone Levels With Left Ventricular Hypertrophy in Primary Hypertension. |
| Q53362202 | Development of novel nomograms to predict renal functional outcomes after laparoscopic adrenalectomy in patients with primary aldosteronism. |
| Q38383249 | Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists |
| Q36174691 | Effect of Treatment on Body Fluid in Patients with Unilateral Aldosterone Producing Adenoma: Adrenalectomy versus Spironolactone. |
| Q52987175 | Evolution of computed tomography-detectable adrenal nodules in patients with bilateral primary aldosteronism. |
| Q47587882 | Lateralization index but not contralateral suppression at adrenal vein sampling predicts improvement in blood pressure after adrenalectomy for primary aldosteronism |
| Q58760700 | Lipocalin-2 derived from adipose tissue mediates aldosterone-induced renal injury |
| Q33772765 | Management of hypertension in primary aldosteronism |
| Q37976974 | Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension |
| Q47783590 | NT-proBNP, a useful tool in hypertensive patients undergoing a diagnostic evaluation for primary aldosteronism. |
| Q37938722 | Newborn screening and renal disease: where we have been; where we are now; where we are going |
| Q92201017 | Predicting factors related with uncured hypertension after retroperitoneal laparoscopic adrenalectomy for unilateral primary aldosteronism |
| Q90219809 | Primary Aldosteronism Associated with Multiple Adrenocortical Micronodules in a Patient with Renal Cell Carcinoma |
| Q37951385 | Primary aldosteronism: from bench to bedside |
| Q52657939 | Progress in the Management of Primary Aldosteronism. |
| Q38985182 | Proportion of Patients With Hypertension Resolution Following Adrenalectomy for Primary Aldosteronism: A Systematic Review and Meta-Analysis. |
| Q43630822 | Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone |
| Q40618492 | Risk of New-Onset Dyslipidemia After Laparoscopic Adrenalectomy in Patients with Primary Aldosteronism |
| Q44642659 | Salt, Aldosterone, and Parathyroid Hormone: What Is the Relevance for Organ Damage? |
| Q36588567 | Time course and factors predicting arterial stiffness reversal in patients with aldosterone-producing adenoma after adrenalectomy: prospective study of 102 patients. |
| Q38527834 | Treatment of Primary Aldosteronism and Organ Protection |
| Q48181150 | Urinary corticosteroid excretion predicts left ventricular mass and proteinuria in chronic kidney disease |
Search more.